Condition
Gastroenteritis Escherichia Coli
Total Trials
5
Recruiting
0
Active
0
Completed
4
Success Rate
80.0%-7% vs avg
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
80.0%
-6.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results80% success
Data Visualizations
Phase Distribution
5Total
P 1 (5)
Trial Status
Completed4
Terminated1
Trial Success Rate
80.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT01147445Phase 1CompletedPrimary
Phase I Study of ETEC Vaccine
NCT03548064Phase 1TerminatedPrimary
A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area
NCT00654108Phase 1CompletedPrimary
Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects
NCT02531685Phase 1CompletedPrimary
Phase 1 Study of dmLT ID Vaccination in Healthy Adults
NCT02052934Phase 1CompletedPrimary
Safety of Sublingual dmLT for ETEC
Showing all 5 trials